FDA whakapaia e Vosevi mo Hepatitis C

Te US Kai me te Drug Whakahaere whakaaetia tenei ra Vosevi ki te hamani pakeke ki kakā huaketo C (HCV) ngā tohuira 1-6 kahore cirrhosis (mate ate) ranei ki te cirrhosis ngawari. Vosevi Ko te-horopeta whakaritea, huinga papa kei roto e rua taero whakaaetia i mua - sofosbuvir me velpatasvir - me te tarukino hou, voxilaprevir. Vosevi Ko te maimoatanga tuatahi whakaaetia hoki tūroro e kua tukinotia mua ki te sofosbuvir tika-mahi patu huaketo tarukino ranei te tahi atu raau taero mō te HCV e tautāwhi i te pūmua i huaina NS5A.

"Ārai taero patu huaketo Direct-mahi i te huaketo i whakanuia a maha whakaora HCV. whakarato Vosevi he kōwhiringa maimoatanga mō te tahi mau tūroro kihai i nei pai te tukinotia ki ētahi atu taero HCV i te mua, "ka mea a Edward Cox, MD, kaiwhakahaere o te Tari o antimicrobial Products i Center o te FDA mo Drug Aromātai a Rangahau.

Hepatitis C Ko te mate viral e ai mumura o te ate e taea arahi ki mahi ate iti rahunga ate ranei. E ai ki nga Senitā mo me te Ārai Tahumaero, he whakatau tata 2.7 ki te 3.9 miriona iwi i roto i te United States i HCV ma'i. kia whai jaundice (kanohi kowhai kiri ranei) ētahi tūroro e mamae i te mate HCV ma'i i runga i nga tau maha, me te whakawhanake i pōauautanga, pērā i toto, whakaeminga wai i roto i te puku, mate, mate pukupuku ate me te mate.

E i te iti rawa e ono tohuira motuhake HCV, ranei taumahatanga, e he ira rōpū motuhake o te huaketo. E matau te matatu o te huaketo e taea te āwhina i ngā tūtohutanga maimoatanga. Tata 75 ōrau o Ameliká ki HCV i tohuira 1; 20-25 ōrau i ngā tohuira 2 3 ranei; a ka e huaketo he maha iti o tūroro ki ngā tohuira 4, 5 6 ranei.

arotakea te haumaru, me te aonga o Vosevi i roto i Tauwähi 3 tamataraa haumanu rua e whakaurua āhua 750 ngā pakeke, kahore cirrhosis ranei ki cirrhosis ngawari.

whakaritea te tamataraa tuatahi 12 wiki o Vosevi maimoatanga ki placebo i roto i ngā pakeke ki te tohuira 1 nei i rahua mua maimoatanga ki te tarukino NS5A inhibitor. Tūroro ki tohuira 2, 3, 4, 5 6 ranei katoa riro Vosevi.

whakaritea te tamataraa tuarua 12 wiki o Vosevi ki te taero whakaaetia i mua sofosbuvir me velpatasvir i roto i ngā pakeke ki ngā tohuira 1, 2 3 ranei nei i rahua mua maimoatanga ki sofosbuvir engari e kore te tarukino NS5A inhibitor.

faaite Hua o mau tamataraa e rua e i 96-97 ōrau o tūroro e riro Vosevi kahore huaketo kitea i roto i te toto 12 wiki i muri i te mutunga o maimoatanga, e parau e kua whakaorangia mate tūroro '.

He rerekē tūtohutanga maimoatanga mō Vosevi i tohuira viral me te hītori maimoatanga mua rānei.

Ko te tauhohe kino tino noa i roto i te tūroro tango Vosevi i ānini, rohirohi, korere me te whakapairuaki.

contraindicated Vosevi te i roto i te tūroro tango i te rifampin tarukino.

Hepatitis B huaketo i korerotia (HBV) faaitoitoraa i roto i te HCV / HBV tūroro coinfected pakeke nei i pangia ranei i oti maimoatanga ki HCV antivirals tika-mahi, me te hunga kihai i te fariiraa i HBV therapy patu huaketo. HBV faaitoitoraa i roto i te tūroro peratia ki hāngai-mahi rongoa patu huaketo e taea hua i roto i ngā raruraru ate nui ranei te mate i roto i te tahi mau tūroro. kia hipoki ngaio tiaki hauora tūroro katoa hoki taunakitanga o te mate HBV nāianei mua ranei i mua i te tīmata maimoatanga ki Vosevi.

Whakaaetia te FDA tenei tono  Arotake matua  me te  Haumanu pakaruhanga iku'anga.  
 
The FDA granted approval of Vosevi to Gilead Sciences Inc.

Te FDA, he pokapū i roto i te Tari US o Hauora me Ratonga Human, tiaki te hauora tūmatanui mā te haapapū i te haumaru, tōtika, me te haumaru o te tangata, me te kararehe taero, kano, me ētahi atu hua koiora mō te whakamahi tangata, me ngā pūrere hauora. hoki te kawenga mō te te haumaru me te haumaru o te supply o to tatou iwi kai, poke, tāpiringa kai, hua e hoatu atu radiation hiko, me mo te ture hua tupeka te ti'amâraa.

Tukua tou karere ki a tatou:

ENQUIRY NOW
  • * CAPTCHA: koa tīpako i te Tree


wā Post: Whiringa-24-2017
WhatsApp Online Chat !